Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYK vs TMO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SYK Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 4–6 Matrix Metrics)

SYK Overall Winner 6-Pillar Tally: SYK 5 – 1 TMO Matrix Metrics: SYK 4 – 6 TMO

As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Thermo Fisher Scientific, Inc. (TMO) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas TMO carries 48.6/100 (HOLD) at $693.73 (25.2x Forward P/E, 19.1% operating margin).

  • Composite vs. Pillar Nuance: While TMO currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. SYK 46.5/100 HOLD), SYK captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (24.0% vs. 19.1% operating margin) and revenue trajectory (+7.6% vs. +9.1% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYK vs TMO
SYK NYSE Head-to-Head Winner
Stryker Corporation
Surgical & Medical Instruments & Apparatus
$310.79
+0.37% 1D
Market Cap $118.9B
TTM Revenue $26.3B
Forward P/E 19.0x
Beta / 30D Vol 0.22β · 50% Vol
Unified Composite Score
46.5 / 100 HOLD
Tech 37.0 Fund 49.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.5 · SMA20: $312.55 · SMA50: $292.40
TMO NYSE
Thermo Fisher Scientific, Inc.
Measuring & Controlling Devices, Nec
$693.73
-0.93% 1D
Market Cap $259.2B
TTM Revenue $47.4B
Forward P/E 25.2x
Beta / 30D Vol 0.61β · 31% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 35.0 Fund 47.0 Flow 57.0 Mom 41.8
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.3% over 20 days), RSI 53
RSI-14: 53.0 · SMA20: $696.72 · SMA50: $672.31

6-Pillar Scorecard Institutional Category Breakdown (SYK 5 – 1 TMO)

Columns: Metric · SYK · TMO
1. Valuation Multiples SYK
Forward P/E 19.0x 25.2x
Trailing P/E 33.3x 36.9x
PEG Ratio 1.54x 2.08x
EV / Revenue 5.0x 6.2x
2. Growth & Scale TMO
Revenue Growth (YoY) +7.6% +9.1%
Earnings Growth (YoY) -11.7% +8.7%
TTM Revenue (USD) $26.3B $47.4B
Market Cap $118.9B $259.2B
3. Profitability & Quality SYK
Gross Margin 65.7% 41.3%
Operating Margin 24.0% 19.1%
Net Profit Margin 13.8% 14.9%
Return on Equity (ROE) 16.0% 13.4%
4. Balance Sheet & Cash Flow SYK
Cash Generation (TTM) $4.57B $7.60B
Cash Flow Margin 17.4% 16.0%
Net Cash / Leverage $11.7B Net Debt (0.64x D/E) $35.9B Net Debt (0.76x D/E)
Dividend Yield 1.10% 0.26%
5. Options & Positioning SYK
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 28.1% (5th %ile) 35.2% (4th %ile)
Put/Call OI Skew 0.30x (Call-Skewed) 0.57x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat SYK
OpEx & R&D Intensity 41.7% of Rev ($11.0B) 22.2% of Rev ($10.5B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Concentrated Oligopoly Moat High Switching-Cost Moat
Supply-Chain Role Medical Devices Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYK (4) vs TMO (6)
Institutional Metric SYK TMO Criterion Row Edge
Market Capitalization
Scale
$118.9B $259.2B Larger Scale TMO
Trailing P/E Ratio
Valuation
33.3x 36.9x Lower Multiple SYK
Forward P/E Ratio
Valuation
19.0x 25.2x Lower Multiple SYK
Revenue Growth (YoY)
Growth
+7.6% +9.1% Higher Growth TMO
Operating Margin (TTM)
Profitability
24.0% 19.1% Higher Margin SYK
Net Profit Margin
Profitability
13.8% 14.9% Higher Margin TMO
Return on Equity (ROE)
Capital Efficiency
16.0% 13.4% Higher ROE SYK
52-Week Range Position
Momentum
36% ($267–$389) 88% ($435–$728) Stronger Trend TMO
Beta / 30D Volatility
Risk Regime
0.22β · 50% Vol 0.61β · 31% Vol Lower Realized Risk TMO
Unified Institutional Score
Composite Signal
46.5 / 100 (HOLD) 48.6 / 100 (HOLD) Higher Composite TMO
Trailing 12M Revenue (USD)
Operating Scale
$26.3B $47.4B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.7% 41.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.54x PEG · 5.0x EV/Rev 2.08x PEG · 6.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$4.57B ($11.7B Net Debt (0.64x D/E)) $7.60B ($35.9B Net Debt (0.76x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYK +4.93 pp
SYK: +5.47% · TMO: +0.54%
3M Horizon TMO +23.98 pp
SYK: -6.21% · TMO: +17.77%
6M Horizon TMO +57.73 pp
SYK: -0.78% · TMO: +56.95%
1Y Horizon TMO +36.35 pp
SYK: -16.77% · TMO: +19.58%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SYK Revenue TMO Revenue SYK Op. Margin TMO Op. Margin Margin Leader
FY2018 $13.6B $24.4B 18.7% 15.5% SYK
FY2019 $14.9B $25.5B 18.2% 18.0% SYK
FY2020 $14.3B $32.2B 15.5% 24.2% TMO
FY2021 $17.1B $39.2B 15.1% 25.6% TMO
FY2022 $18.4B $44.9B 15.4% 18.7% TMO
FY2023 $20.5B $42.9B 19.0% 16.0% SYK
FY2024 $22.6B $42.9B 16.3% 17.1% TMO
FY2025 $25.1B $44.6B 19.5% 17.4% SYK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYK SURGE
8d in phase · OBV DISTRIBUTION
Current IV 28.1%
IV Percentile 5th %ile
Put/Call OI Skew 0.30x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact SYK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TMO CONSOLIDATION
44d in phase · OBV NEUTRAL
Current IV 35.2%
IV Percentile 4th %ile
Put/Call OI Skew 0.57x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TMO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYK Moat Profile Concentrated Oligopoly Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $118.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($11.0B)
90D Engineering Disclosures 0 Published · Surgical Robotics
TMO Moat Profile High Switching-Cost Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $259.2B market capitalization and 19.1% operating margin.
OpEx & R&D Reinvestment 22.2% of Rev ($10.5B)
90D Engineering Disclosures 0 Published · Spatial Genomics

Investor FAQ SYK vs TMO Key Questions & Quantitative Answers

As of Nov 16, 2026, Stryker Corporation (SYK) is the stronger overall head-to-head candidate over Thermo Fisher Scientific, Inc. (TMO) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SYK carries a Unified Composite Score of 46.5/100 (HOLD) at $310.79 (19.0x Forward P/E, 24.0% operating margin), whereas TMO carries 48.6/100 (HOLD) at $693.73 (25.2x Forward P/E, 19.1% operating margin). Composite vs. Pillar Nuance: While TMO currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. SYK 46.5/100 HOLD), SYK captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (24.0% vs. 19.1% operating margin) and revenue trajectory (+7.6% vs. +9.1% YoY).

TMO leads the Growth & Scale pillar: SYK posts +7.6% YoY revenue growth and -11.7% YoY earnings growth on $26.3B TTM revenue (65.7% gross margin, 24.0% operating margin), compared with TMO at +9.1% YoY revenue growth and +8.7% YoY earnings growth on $47.4B TTM revenue (41.3% gross margin, 19.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SYK cumulative revenue shifted +84.7% while TMO shifted +82.9%. In operating R&D and SG&A reinvestment, SYK deploys 41.7% of Rev ($11.0B) (0 90-day corporate R&D disclosures) versus 22.2% of Rev ($10.5B) (0 disclosures) for TMO.

SYK screens cheaper on headline valuation multiples. SYK trades at 19.0x Forward P/E, 33.3x Trailing P/E, 1.54x PEG, and 5.0x EV/Revenue (17.4% FCF margin), whereas TMO trades at 25.2x Forward P/E, 36.9x Trailing P/E, 2.08x PEG, and 6.2x EV/Revenue (16.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYK (16.0% ROE) versus TMO (13.4% ROE) capital efficiency.

In options market volatility and institutional positioning, SYK carries 28.1% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.30x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.22β · 50% Vol realized risk). By comparison, TMO carries 35.2% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.61β · 31% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.